By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel has a bearish consensus on Bristol-Myers Squibb (BMY), citing the unsustainability of its dividend due to declining legacy revenue, the risk of M&A integration failures, and the potential impact of higher discount rates.
Risk: The unsustainability of the dividend due to declining legacy revenue and the risk of M&A integration failures.
Opportunity: Not explicitly stated, but implied as the potential success of new drugs like Opdivo biosimilars or other pipeline wins.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Bristol checks a lot of boxes for investors seeking stability and reliability.
The company's stock is less prone to wild price swings than the broader market on average.
The dividend payout has been increased annually for 17 consecutive years.
Bristol Myers Squibb (NYSE: BMY) has been on a decent run over the past year, with the stock price climbing more than 20%. That may be surprising to some, as the company expects lower sales in 2026 than in 2025.
On the surface, that does sound like enough to keep some investors away.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
With Bristol Myers, however, there's more than meets the eye, and its low volatility and high dividend yield are major draws for other investors.
Bristol Myers faces slowing sales from its legacy portfolio, with revenue sliding to $21.8 billion in 2025, a noticeable drop from the $25.7 billion reported in 2024. Investors are also worried about Eliquis, its blood thinner drug, facing an upcoming patent expiration.
Adding to the worries, Bristol expects total revenue to slow in 2026, coming in between $46 billion and $47.5 billion compared to the $48.2 billion it reported in 2025.
The company, however, is showing progress in its growth portfolio. Sales for that segment of the business climbed from $22.6 billion in 2024 to $26.4 billion in 2025, helping offset the decline in legacy portfolio revenue.
There are short-term and long-term considerations to be aware of. With slowing revenue, no one can be sure how the markets will react to the company's Q1 2026 earnings report, scheduled for release on April 30.
Looking beyond the next week, Bristol offers stability with an exceptionally low beta of 0.2. While the broader markets may get choppy, Bristol stock isn't prone to volatile price swings. Pair that with a solid dividend payout that's been increased annually for 17 consecutive years and is currently yielding 4.2%, and it's a company worth consideration for building a position in, thanks to low volatility and a high dividend yield.
Before you buy stock in Bristol Myers Squibb, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $498,522! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,276,807!
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 200% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of April 26, 2026. *
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"BMY's reliance on dividend yield and low beta masks a fundamental erosion of earnings power that makes the current payout ratio increasingly precarious."
The article leans on BMY's 4.2% dividend yield and low 0.2 beta as a safety net, but this is a classic value trap setup. While the 'growth portfolio' is expanding, the company is essentially cannibalizing its own margins to fund M&A-driven growth to replace the inevitable Eliquis patent cliff. Trading at a depressed forward P/E, the market is pricing in a permanent impairment of earnings power, not just a cyclical dip. Relying on dividends while the core revenue base erodes is a dangerous game; unless the new pipeline assets show blockbuster clinical outcomes by Q3, the dividend payout ratio could become unsustainable, forcing a pivot from 'income play' to 'capital preservation' mode.
If BMY's recent acquisitions in oncology and immunology prove to be high-margin cash cows, the current valuation represents a significant discount that ignores the company's ability to maintain its dividend through sheer scale.
"BMY's 2026 revenue guide of $46-47.5B versus $48.2B in 2025 reveals deceleration that tempers its low-volatility dividend appeal unless growth products overdeliver."
BMY's 0.2 beta and 4.2% yield with 17 straight dividend hikes make it a defensive haven amid market chop, especially as growth portfolio sales surged 17% to $26.4B in 2025, cushioning legacy's 15% drop to $21.8B for flat total revenue at $48.2B. Yet 2026 guidance of $46-47.5B signals deceleration, with Eliquis patent expiry unaddressed in scale—likely a multi-billion hit. Q1 2026 earnings on April 30 will probe if new drugs like Opdivo biosimilars or others ramp fast enough. Solid for income now, but patent cliffs demand pipeline wins to avoid margin squeeze and yield trap.
The growth portfolio's momentum could accelerate beyond 2026 guidance if clinical trials succeed, fully offsetting legacy declines and enabling further dividend hikes without strain.
"BMY's low volatility and high dividend are compensation for structural revenue decline, not insurance against it—and the market's 20% run suggests the yield is already fully valued."
BMY is being sold as a defensive dividend play—low beta (0.2), 4.2% yield, 17-year streak of increases. But the article buries the real story: revenue declining from $25.7B (2024) to $21.8B (2025), with further contraction expected in 2026. That's not stability; that's secular decline masked by portfolio rotation. The growth segment ($26.4B in 2025) is offsetting legacy erosion, but we don't know if that growth is sustainable or if it's just timing from recent acquisitions. Eliquis patent cliff looms. A 20% stock run on shrinking sales suggests the market has already priced in the dividend—leaving little margin for safety if growth portfolio disappoints or dividend coverage deteriorates.
If BMY's growth portfolio compounds at 8-10% annually while legacy declines slow, the company could stabilize revenue by 2027-2028 and re-rate higher on improving margins; defensive investors genuinely do need 4.2% yield with low volatility in a choppy macro environment.
"The biggest risk to the constructive reading is that Eliquis’ patent expiry and ongoing legacy declines could outpace growth portfolio gains, potentially hurting earnings and prompting multiple compression despite the dividend."
The article highlights BMY’s low volatility and 4.2% yield as retirement-friendly ballast, but it glosses over real risk that could derail that thesis. A sizable drag is the legacy portfolio, with 2025 revenue of $48.2B expected to drop to $46–$47.5B in 2026, while Eliquis faces patent cliffs that threaten future cash flow. The growth portfolio must carry the load, and the expansion may take longer than implied. Valuation context is missing: a defensively tilted stock with a high dividend can still underperform if discount rates rise or the pipeline stalls. In short, stability may come at a growing earnings risk.
The strongest counterpoint is that Bristol’s cash flow remains robust enough to sustain the dividend even amid legacy declines, and a few near-term pipeline milestones could prove more durable than feared, supporting earnings and a possible re-rating of the multiple. In risk-off conditions, defensives can outperform and the stock’s low beta may actually cushion a drawdown, making the bear case less clear-cut.
"BMY's M&A-heavy strategy creates integration risks that threaten long-term solvency more than the dividend yield suggests."
Claude, you’re missing the capital allocation reality: BMY isn't just 'rotating' portfolios; it’s aggressively leveraging its balance sheet for M&A to buy time. The real risk isn't just the Eliquis cliff—it’s the integration risk of these high-priced acquisitions (like Karuna) which are currently diluting ROIC. If these assets don't deliver, the dividend isn't just a 'yield trap'—it becomes a strategic mistake that prevents BMY from deleveraging or investing in internal R&D, creating a long-term liquidity crunch.
"BMY's revenue scale and growth offset cushion M&A risks better than implied, but macro discount rates pose a new threat."
Gemini, aggressive M&A is risky, but your liquidity crunch overlooks BMY's defensive moat: $48.2B revenue scale funds integration without strain, and 17% growth portfolio surge ($26.4B) already offsets legacy erosion. Unflagged risk: if macro forces higher discount rates, even low-beta yield plays compress multiples. Still, 2026 guidance implies 1-2% organic growth needed—achievable if Opdivo ramps hold.
"The dividend is mathematically vulnerable if legacy decline accelerates and growth portfolio growth stalls—a scenario the panel hasn't stress-tested with actual payout ratio math."
Grok flags discount rate compression as unflagged risk—valid. But nobody's quantified the actual payout ratio stress. If legacy revenue drops 5-7% annually through 2027 while growth portfolio plateaus at mid-single digits, FCF could compress 15-20%. At current $0.24/share quarterly dividend, that's unsustainable without asset sales or leverage increases. Gemini's integration risk + Grok's macro headwind = a dual squeeze that makes 2026 earnings the real inflection point, not just Q1 results.
"The real test for BMY’s dividend is ROIC and FCF coverage on new acquisitions; without double-digit ROIC and solid FCF, the payout becomes unsustainable."
Gemini is right to flag M&A integration risk, but you overstate the safety of the dividend by focusing on scale. The bigger lever is ROIC on Karuna and other acquisitions—if 2026-27 returns don’t clear a double-digit ROIC and FCF coverage stays near or below 1x dividend, the payout becomes unsustainable without more leverage or asset sales. The 2026 guidance may imply near-term stability, but the longer-term risk is a liquidity crunch if margins erode.
The panel has a bearish consensus on Bristol-Myers Squibb (BMY), citing the unsustainability of its dividend due to declining legacy revenue, the risk of M&A integration failures, and the potential impact of higher discount rates.
Not explicitly stated, but implied as the potential success of new drugs like Opdivo biosimilars or other pipeline wins.
The unsustainability of the dividend due to declining legacy revenue and the risk of M&A integration failures.